Back

Effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, on diuresis and neurohormonal activation in type 2 diabetes mellitus and heart failure

29 August 2016 (10:26 - 10:33)
Organised by:
Congress Presentation Part of: Novel pharmacological therapy in chronic heart failure Pharmacologic therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Tetsushiro Takeuchi

Mie University Graduate School of Medicine, Tsu (Japan)

6 More presentations in this session

Presentation thumbnail
Contribution of central donepezil to prevention of cardiac dysfunction and improvement of long-term survival in chronic heart failure rats after myocardial infarction
Doctor M. Li (Osaka, JP)
Abstract Slides
Presentation thumbnail
Stimulation of the soluble guanylate cyclase attenuates pressure-overload induced cardiac hypertrophy in mice
Doctor J. Ruedebusch (Greifswald, DE)
Abstract
Presentation thumbnail
Magnesium orotate improves symptoms, exercise capacity and quality of life in patients with valve prosthesis: results from a randomized, open-label, case-control 2-year study
Professor I. Gaisin (Izhevsk, RU)
Abstract Slides
Presentation thumbnail
Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes
Doctor P. Kolkhof (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
The CaMKII inhibitor RA123456 attenuates heart failure and prevents ventricular and atrial arrhythmias in vivo
Mr J. Mustroph (Regensburg, DE)
Abstract Slides

Access the full session

Session thumbnail
Novel pharmacological therapy in chronic heart failure

The Event

Event poster

ESC Congress 2016

29 August 2016 10:26 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources